ardeparin

BACKGROUND The optimal duration of prophylaxis against venous thromboembolism after total hip or knee replacement is uncertain… (More)

In addition to its anticoagulant effects, heparin is known to have antiproliferative effects on vascular smooth muscle cells… (More)

BACKGROUND Ardeparin sodium has recently received approval by the Food and Drug Administration for prophylaxis against venous… (More)

UNLABELLED We performed a double-blind, randomized clinical trial to compare the efficacy and safety of three different… (More)

Ardeparin sodium (Normiflo, Wyeth-Ayerst) is a low molecular weight heparin undergoing clinical evaluation as an antithrombotic… (More)

BACKGROUND Deep vein thrombosis is common in patients undergoing major knee surgery. Static graduated compression stockings… (More)

Ardeparin is a low molecular weight heparin currently being evaluated as an antithrombotic agent. The objective of this… (More)

This prospective, uncontrolled trial explored the relationship between varying dosages of a low molecular weight heparin (LMWH… (More)

Osteoporosis is a well-recognized complication of long-term heparin use. However, the mechanisms by which heparin can influence… (More)

We have compared the non-specific binding of unfractionated heparin (UFH) with that of low molecular weight heparin (LMWH) to… (More)